Positive Phase III results for Lilly's bamlanivimab and etesevimab for early COVID-19

11 March 2021

US pharma major Eli Lilly (NYSE: LLY) yesterday announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase III study, demonstrating bamlanivimab (LY-CoV555) 700mg and etesevimab (LY-CoV016) 1,400mg together significantly reduced COVID-19 related hospitalizations and deaths ("events") in high-risk patients recently diagnosed with COVID-19.

These results provide additional efficacy and safety data that support the use of the dose recently granted both Emergency Use Authorization by the US Food and Drug Administration and a positive scientific opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), said Lilly.

Coincidentally, the EMA today announced that it has started a ‘rolling review’ of data on the antibodies cocktail of bamlanivimab and etesevimab to be used in combination for the treatment of COVID-19. The review will also look at bamlanivimab used alone.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK